免疫肿瘤学试验报告(TRIO):ASCO-SITC声明
ASCO与SITC召集工作组制定TRIO推荐,以改善免疫肿瘤学(IO)临床试验报告,涵盖疗效、毒性及联合序贯等独特方面。推荐基于专家共识,因现有支持证据有限,旨在提供更完整的获益风险证据,并需随领域发展定期修订。
要点
- TRIO推荐针对IO试验的疗效、毒性及联合序贯报告提供共识框架。
- 推荐基于专家共识,现有证据有限,需定期更新。
- 目标为提升IO试验报告完整性,支持获益风险评价。
核心结论
- TRIO推荐旨在改善IO临床试验报告,提供更完整的相对获益与风险证据。
研究设计与样本
- ASCO与SITC召集由肿瘤内科医生、免疫学家、临床研究者、生物统计学家及产业和政府代表组成的工作组制定推荐。
- 推荐基于专家共识,因现有支持证据有限。
临床怎么用
- 将TRIO推荐用于IO临床试验的报告设计,以提升证据完整性。
局限性
- 推荐基于专家共识而非充分证据,且需随IO领域发展定期修订。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To develop recommendations for clinical trial reporting that address the unique efficacy, toxicity, and combination and sequencing aspects of immuno-oncology (IO) treatments. METHODS: ASCO and the Society for Immunotherapy of Cancer (SITC) convened a working group that consisted of practicing medical oncologists, immunologists, clinical researchers, biostatisticians, and representatives from industry and government to develop Trial Reporting in Immuno-Oncology (TRIO) recommendations. These recommendations are based on expert consensus, given that existing data to support evidence-based recommendations are limited. CONCLUSION: The TRIO recommendations are intended to improve the reporting of IO clinical trials and thus provide more complete evidence on the relative benefits and risks of an IO therapeutic approach. Given the rapid expansion of the number of IO clinical trials and ongoing improvements to the evidence base supporting the use of IO treatments in clinical care, these recommendations will likely need regular revision as the IO field develops.
引用
- Tsimberidou AM, Levit LA, Schilsky RL, et al. Trial Reporting in Immuno-Oncology (TRIO): An American Society of Clinical Oncology-Society for Immunotherapy of Cancer Statement. J Clin Oncol. 2018. PMID: 30339040. doi:10.1200/JCO.18.00145
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。